A new study has uncovered a protein-related abnormality that may explain some of the communication difficulties commonly associated with autism spectrum disorder. Researchers from the Daegu Gyeongbuk Institute of Science and Technology in South Korea investigated a protein known as collybistin, which is essential for healthy communication between brain cells. Their findings provide new insight into how disruptions in brain signaling may contribute to social and language-related challenges.
Scientists discovered that mutations in the ARHGEF9 gene, responsible for producing collybistin, interfere with inhibitory signalling in the brain. When this process is disrupted, communication between neurons becomes less stable and efficient.
To better understand the effects, the research team conducted experiments on mice lacking collybistin in the prefrontal cortex, the brain region linked to decision-making, communication, and social interaction. These mice showed significant defects in inhibitory synapses, which are structures that help control neural activity. They believe this finding may resemble communication impairments observed in some individuals with autism.
The study also revealed that collybistin works closely with another protein called gephyrin, which helps maintain inhibitory synapses. Reduced collybistin activity weakened gephyrin function, further disturbing the brain’s signaling balance. According to the researchers, this imbalance may play a direct role in communication and behavioral difficulties.
Scientists believe the findings could open the door to future treatments aimed at restoring inhibitory signaling in the brain. Additional research will focus on whether targeting these protein pathways could eventually help improve communication-related symptoms in neurodevelopmental disorders such as autism.
Professor Ko stated,
“This study has significantly advanced our understanding of the pathophysiology of neurodevelopmental disorders, particularly autism spectrum disorder.”
Professor Eom said,
“We will expand our collybistin-gephyrin gene research to human cell models and into preclinical studies.”
